INNOVIVA, INC. Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders
INNOVIVA, INC. (INVA) reported Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders of $69.81 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Shareholders' Equity
us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders · last filed 2025-02-26
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2022-09-30 was $53.76M, a 994.44% increase year-over-year.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2022-06-30 was $9.54M, a 52.66% decline year-over-year.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2022-03-31 was $6.51M, a 69.43% decline year-over-year.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for the quarter ending 2021-09-30 was $4.91M.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2022 was $69.81M, a 17.41% increase from fiscal 2021.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2021 was $59.46M, a 95.11% increase from fiscal 2020.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2020 was $30.47M, a 188.77% increase from fiscal 2019.
- INNOVIVA, INC. noncontrolling interest, decrease from distributions to noncontrolling interest holders for fiscal 2019 was $10.55M, a 77.21% increase from fiscal 2018.
| Period end | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 3 month | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 6 month | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 9 month | Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders 12 month |
|---|---|---|---|---|
| 2022-12-31 | $69.81M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $53.76M 10-Q · filed 2023-11-01 | $63.30M derived: sum of 2 quarters · filed 2023-11-01 | $69.81M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $9.54M 10-Q · filed 2023-11-01 | $16.05M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $6.51M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $59.46M 10-K/A · filed 2024-03-05 | |||
| 2021-09-30 | $4.91M 10-Q · filed 2022-11-09 | $25.07M derived: sum of 2 quarters · filed 2022-11-09 | $46.36M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $20.16M 10-Q · filed 2022-11-09 | $41.45M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $21.29M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $30.47M 10-K · filed 2023-02-28 | |||
| 2020-06-30 | $12.15M 10-Q · filed 2021-10-27 | $27.96M derived: sum of 2 quarters · filed 2021-10-27 | ||
| 2020-03-31 | $15.81M 10-Q · filed 2021-10-27 | |||
| 2019-12-31 | $10.55M 10-K/A · filed 2022-03-17 | |||
| 2019-09-30 | $10.55M 10-Q · filed 2020-10-28 | |||
| 2018-12-31 | $5.96M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $1.99M 10-Q · filed 2019-10-30 | $2.80M derived: sum of 2 quarters · filed 2019-10-30 | $2.89M derived: sum of 3 quarters · filed 2019-10-30 | |
| 2018-06-30 | $809.00K 10-Q · filed 2019-10-30 | $899.00K derived: sum of 2 quarters · filed 2019-10-30 | ||
| 2018-03-31 | $90.00K 10-Q · filed 2019-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |